Literature DB >> 7081815

Rapidly decreasing forced expiratory volume in one second or vital capacity and development of chronic airflow obstruction.

J Clément, K P Van de Woestijne.   

Abstract

In a prospective study of 2,406 members of the Belgian Air Force, followed for 3 to 15 yr, 325 demonstrated a yearly decline in FEV1 and/or in vital capacity (VC) that was significantly faster than that expected in healthy nonsmokers. Such rapid declines were met more frequently in heavy smokers and in subjects with a reduced FEV1 or VC. There was no clear-cut association between rapid declines and a history of respiratory diseases. It may be predicted, if the rates of declines do not vary with aging, that about 0.5% of nonsmokers and 4% of heavy smokers in the investigated population will reach disabling airway obstruction (FEV1 of 1.2 L or less) at 65 yr of age. At least 6 to 8 yr of follow-up are required to appreciate with precision the rates of declines in FEV1 or in VC.

Entities:  

Mesh:

Year:  1982        PMID: 7081815     DOI: 10.1164/arrd.1982.125.5.553

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  4 in total

1.  The UCLA population studies of CORD: X. A cohort study of changes in respiratory function associated with chronic exposure to SOx, NOx, and hydrocarbons.

Authors:  R Detels; D P Tashkin; J W Sayre; S N Rokaw; F J Massey; A H Coulson; D H Wegman
Journal:  Am J Public Health       Date:  1991-03       Impact factor: 9.308

Review 2.  Systematic review with meta-analysis of the epidemiological evidence relating smoking to COPD, chronic bronchitis and emphysema.

Authors:  Barbara A Forey; Alison J Thornton; Peter N Lee
Journal:  BMC Pulm Med       Date:  2011-06-14       Impact factor: 3.317

Review 3.  Natural history of emphysema.

Authors:  Omar A Minai; Joshua Benditt; Fernando J Martinez
Journal:  Proc Am Thorac Soc       Date:  2008-05-01

Review 4.  Systematic review of the evidence relating FEV1 decline to giving up smoking.

Authors:  Peter N Lee; John S Fry
Journal:  BMC Med       Date:  2010-12-14       Impact factor: 8.775

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.